Krystal Biotech (NASDAQ:KRYS – Get Free Report) posted its quarterly earnings data on Monday. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.07, Briefing.com reports. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The company had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. During the same period in the previous year, the business earned ($0.67) EPS. Krystal Biotech’s revenue for the quarter was up 879.9% compared to the same quarter last year.
Krystal Biotech Stock Up 2.1 %
KRYS opened at $174.41 on Wednesday. The company’s 50-day moving average price is $181.81 and its 200 day moving average price is $180.23. Krystal Biotech has a fifty-two week low of $93.95 and a fifty-two week high of $219.34. The firm has a market cap of $5.01 billion, a price-to-earnings ratio of 98.54 and a beta of 0.82.
Insider Buying and Selling at Krystal Biotech
In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now directly owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 14.10% of the stock is currently owned by insiders.
Analysts Set New Price Targets
View Our Latest Stock Report on KRYS
Krystal Biotech Company Profile
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Featured Stories
- Five stocks we like better than Krystal Biotech
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- AMD: The AI Disruptor – Is It Time to Follow Big Tech’s Lead?
- 3 Warren Buffett Stocks to Buy Now
- Analysts Signal Big Upside: Top 3 Stocks to Watch Right Now
- Profitably Trade Stocks at 52-Week Highs
- Bears Misjudged These 3 ETFs: Where Investors Can Find Upside
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.